Phase 1Completed

A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas

A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of Amphinex®-Induced Photochemical Internalisation (PCI) of Gemcitabine in Patients With Advanced Inoperable Cholangiocarcinomas

Sponsor
PCI Biotech AS (Industry)
Enrollment
24 enrolled
Conditions
Cholangiocarcinoma
Interventions
Amphinex, Gemcitabine and Cisplatin
Ages
adults, older adults
Registry
NCT01900158, EUCTR2012-002888-10

Full record on ClinicalTrials.gov

From the registry

This is a Phase I Dose Escalation Study in which the safety, tolerability and efficacy of Amphinex®--induced Photochemical Internalisation (PCI) of Gemcitabine followed by Gemcitabine/Cisplatin Chemotherapy will be assessed in patients with advanced inoperable cholangiocarcinomas.

Primary outcomes

  • Dose-limiting toxicities (DLT) and the safety profile
  • Schedule-limiting toxicities (SLTs) and the safety profile

History

  1. Last registry update

  2. Primary completion

  3. Registered

  4. Started